Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zotarolimus - AbbVie

Next Previous
Drug Profile

Zotarolimus - AbbVie

Alternative Names: ABT 578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm); Resolute Onyx; ZoMaxx; Zotarolimus-eluting coronary stent system

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Medtronic
  • Class Erectile dysfunction therapies; Lactones; Macrolides; Polyenes; Tetrazoles; Vascular disorder therapies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Erectile dysfunction
  • Discontinued Vascular restenosis

Most Recent Events

  • 22 Apr 2021 Medtronic completes the Onyx ONE Clear clinical trial for Coronary artery restenosis in USA and Japan (NCT03647475)
  • 09 Oct 2020 Medtronic Vascular completes the Onyx ONE trial in Coronary artery restenosis in Australia, Austria, Belgium, Bulgaria, France, Hong Kong, Ireland, Italy, Korea, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Slovakia, Spain, Sweden, Switzerland, Thailand and in the UK (NCT03344653)
  • 30 Mar 2020 Safety data from the Onyx ONE Clear clinical trial for Coronary artery released by Medtronic

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top